Clinical Trial Update: A Study to Demonstrate Bioequivalence Between 6 x 2 mg Tablets of Perampanel and a Single 12 mg Tablet of Perampanel in Healthy Subjects [Phase 1]

View source ↗

Summary

This Phase 1 bioequivalence study evaluated whether six 2 mg tablets of perampanel are bioequivalent to a single 12 mg tablet in healthy subjects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Partial-onset Epilepsy

Drugs mentioned

• Perampanel (perampanel)

Snippet

Sponsor: Eisai Inc. | Conditions: Partial Onset Epilepsy | Phase 1 | Status: COMPLETED